cell-based assays
Biocept Licenses CNSide Liquid Biopsy Assay to Plus Therapeutics
Under the agreement, Plus is using the cerebrospinal fluid cell-based assay in its ongoing clinical trial of the radiotherapeutic rhenium 186 obisbemeda.
A recent study showed that the firm's technology could predict glioblastoma patients' chemo responses as well or better than an established genomic biomarker.
Colorectal Cancers Dial up Mutability in Response to Targeted Treatments
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
SEngine Precision Medicine Raises $5.1M in Series A Financing
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.